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ABSTRACT
Introduction: Leptin is a proteohormone produced predominantly by white adipocytes and primarily known for its key role in the 
control of food intake and sense of satiety. From its discover leptin has been found in different body districts, involved in always new 
functions and processes. In the last years numerous relationships between leptin and cancer has been found. The aim of this study is to 
test the leptin positivity in human primitive laryngeal squamous cell carcinoma (SCC) and in its lymph node metastasis.
Materials and methods: Leptin positivity was detected by immunohistochemical analysis on pathological samples from 18 pa-
tients subjected to laryngectomy and neck dissection for SCC.
Results: During the study we pointed out a statistically significant relationship (p < 0.05) between leptin positivity levels and 
tumor differentiation grade, in particular we observed that a decrease in tumor leptin production correlates with higher level of cancer 
histological dedifferentiation.
Conclusion: Our research on leptin expression in laryngeal squamous neoplastic pathology is aimed to the attempt of establish-
ing a more precise patient risk stratification thanks to a new marker able to give a contribution to the identification of patient with poor 
prognosis and at risk of failure of actual standard therapy.
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Introduction
Leptin (from the Greek λεπτός, "thin")(1, 2) is 
a peptidic hormone of 167 amino-acid. It is known 
as “satiety hormone” due to the fact that it plays an 
important monitoring role in the energetic homeo-
stasis, primarily inhibiting hunger and inducing the 
sense of satiety and consequently reducing the food 
intake to regulate the body weight(3).
Leptin was first identified in adipose tissue 
and it was labeled as an adipokine. More recently a 
large number of observations proves that this hor-
mone is secreted in many other different tissues - 
such as gastric fundic glands, skeletal muscle, liver, 
placenta(4) - and situations - as during inflammatory 
processes. Leptin secretion follows the circadian 
rhythm and it reaches its pick during the night(5, 6).
The regulation of leptin serum levels is 
not only related to the adipocyte number and to 
variations in the body weight and nutritional status 
but also to many endocrinological factors, first of 
all the insulin level(4) that, if is too low, inhibits 
leptin production. Leptin secretion is stimulated by 
glucocorticoids, TNF-α (Tumor Necrosis Factor) 
and estrogens, while it is inhibited by β-adrenergic 
activity, androgens, FFA (Free Fatty Acid), GH 
(Growth Hormone) and thyroid hormones.
Leptin receptor belongs to type I cytokine re-
ceptors(7), it is ubiquitously expressed in body in 
3 alternatively spliced forms (long, short and sol-
uble) and each one has a different location where 
plays different role(8).
Leptin has an anorectic effect decreasing the 
food intake(3); it acts also as an insulin-sensitizing 
hormone reducing lipids storage; moreover, lep-
tin promotes catabolic pathways that lead to ATP 
(Adenosine Triphosphate) production and inhibits 
the anabolic processes that require ATP(3).
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Leptin has many other important and various 
effects involving the regulation of immune func-
tion, the interference with bone remodeling(9), the 
promotion of hematopoietic cells proliferation and 
differentiation, the regulation of the reproductive 
system(10, 11) and, during the fetal period, the stim-
ulation of the alveolar surfactant production(12). 
But two remarkable and recently discovered leptin 
functions suggest that this hormone may play an 
important role in the risk of cancer development 
and recurrence: the power of leptin to stimulate an-
giogenesis, endothelial cells growth(13) and proan-
giogenic factors release and its ability to make cells 
avoid stress-induced apoptosis and proliferate(14). 
To date the relation between leptin expression 
and risk of recurrence in laryngeal squamous cell 
carcinoma (SCC) was demonstrated(15) and from 
this assumption, the aim of our study was to test 
leptin positivity in lymph node SCC metastasis 




We selected a series of 18 consecutive pa-
tients, 13 males and 5 females, whose age, at the 
time of diagnosis, was between 43 and 78 years, 
with a mean age of 59 years (61,6 years males; 52,2 
years females). All patients had been subjected to 
total/partial laryngectomy with unilateral/total neck 
dissection in our Operating Unit between 2010 and 
2015. 12 patients had lymph node metastasis at the 
time of the diagnosis.
The characteristics and histopathological fea-
tures of the sample are shown and summarized in 
Table 1.
Sample selection
We picked up 19 samples out of our 18 pa-
tients; each patient sample included 2 specimens: 
the first one taken from a section of larynx primi-
tive tumor without any sign of necrosis, the second 
one taken from one resected lymph node. 12 of the 
lymph nodes included in this study were involved 
by metastasis from laryngeal squamous cell carci-
noma; the 7 lymph nodes negative for metastasis 
were used as negative controls.
The histological grade according to tumor dif-
ferentiation was assessed histologically (Figure 1).
Tissue preparation and histopathologic 
analysis
All samples were fixed in formalin and em-
bedded in paraffin to obtain sections of approxi-
mately 4μm. Sample sections were stained with 
hematoxylin and eosin histochemical staining for 
histological evaluation.
Immunohistochemical analysis
All sections were deparaffinated with xylol, 
rehydrated in a decreasing alcohol scale and sub-
jected to antigenic exposure by 3 cycles of micro-
wave treatment in Tris-HCL/EDTA buffer solution 
(Ph 6) for 5 minutes, led to ambient temperature 
and washed with PBS buffer. After endogenous 
peroxidase activity quenching with 3% hydrogen 
peroxide, all sections were incubated with a pro-
tein blocking buffer for 10 minutes to prevent anti-
bodies nonspecific binding to tissue. Afterwards all 
samples were incubated with the primary antibody 
for one hour at ambient temperature. The primary 
antibody used for the immunohistochemical anal-
ysis is an anti-leptin rabbit polyclonal antibody. 
Primary antibody binding was detected using the 
Labeled StreptAvidin Biotin (LASB+) horseradish 
perossidase (HRP) kit using acetyl-ethanol-car-
bazole as chromogenic substrate for immunohis-
tochemical staining. All sections were contrasted 
with hematoxylin and afterwards were subjected to 
optical microscope evaluation.
All samples included in the study were sub-
sequently histologically reevaluated from two dif-
ferent pathologists to identify the tumor differenti-
ation grade and to highlight eventual vascular and/
or perineural infiltration.
Image analysis
All sections were analyzed to evaluate stain-
ing positivity, intensity and distribution. To rate the 
staining reaction efficacy, adipose tissue, submu-
cosal larynx glands and inflammatory cells (histio-
cytes, lymphocytes and plasma cells) were used as 
positive controls. The staining reaction was evalu-
ated by a team of expert pathologists in a subjective 
semiquantative way using an increasing intensity 
scale going from 0 to 3. The staining was scored 0 
if there was no immunoreactivity, 1 if it was light, 
2 if immunoreactivity was moderate and 3 if tis-
sue response to immunohistochemical staining was 
high.
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Statistical analysis
All statistical analysis were performed using 
VassarStats (©Richard Lowry). Fisher’s exact test 
was used to compare categorical variables. We con-
sidered a p ≤ 0.05 to be significant.
Results
Neoplastic cells showed a variable but statis-
tically significant cytoplasmic positivity to leptin 
(88.9%).
Comparing immunohistochemical charac-
teristics in each case was found a different rate of 
leptin positivity related to clinicopathological char-
acteristic of tumor and especially related to histo-
logical grade (p < 0.05) (Table 1).
There seems to be no statistically significant 
relationship between the intensity of leptin positiv-
ity and sex (p = 0.68) or age (p = 0.64).
In all samples a significant association be-
tween positivity to leptin and tumor histological 
grade was found. Indeed, leptin positivity sharp-
ly raised with the increase of tumor differentiation 
in both laryngeal primitive tumor (p = 0.013) and 
lymph node metastasis specimens (p = 0.03). We 
found the highest staining positivity - grade 3 - in 
all tumor samples (100%) graded as G1 (Figure 2 
a-d) while a negative or minimal positivity – grade 
0/1 - in most (90.9%) G3 labeled samples (Figure 
2 c-f). Moderate leptin expression levels - grade 2 
- were found in most (73.3%) G2 tumor samples 
(Figure 2 b-e).
Furthermore, we observed that the leptin 
immunohistochemical staining positivity level 
showed by lymph node tissue samples was compa-
rable to the primitive laryngeal tumor level only in 
those cases showing the same histological grade.
Laryngeal Squamous Cell Carcinoma (SCC) SCC Lymph Node Metastasis
N (%) Mean age Leptin p value N (%) Mean age Leptin p value
Patients Low (0-1) High (2-3) Low (0-1) High (2-3)
Total 18 59 7 (2-5) 11 (9-2) 12 59.7 8 (3-5) 4 (3-1)
Males 13 (72.2) 61.6 5 (1-4) 8 (7-1)
0.68
8 (66.6) 63.2 5 (3-2) 3 (3-0)
0.59
Females 5 (27.7) 51.2 2 (1-1) 3 (2-1) 4 (33.3) 52.7 3 (0-3) 1 (0-1)
Age
≤59 10 (55.6) 51.6 4 (1-3) 6 (5-1)
0.64
6 (50) 52 3 (1-2) 3 (2-1)
0.27








1 (8.3) 43 -
2
3 (3-0)
1 (0-1) 4 0.03
G2 10 (55.6) 58.8 2 (0-2) 8 (8-0) 57.6 2 (0-2)
G3 Low 6 (33.3) 59.1 5 (2-3) 1 (1-0) 6 (50) 64.3 6 (3-3) -
Table 1: Characteristics and histopathological features of 18 patients and correlation with leptin expression.
Fig. 1: Hematoxylin and eosin staining; MO x10.
a: Well-differentiated (G1) squamous cell carcinoma primitive 
of larynx: note the mild pleomorphism and keratinization; b: 
moderately differentiated (G2) squamous cell carcinoma pri-
mitive of larynx: there is more pleomorphism but the nature 
of the tumor is still readily apparent; c: poorly differentiated 
(G3) squamous cell carcinoma primitive of larynx: there is 
marked pleomorphism but no keratinization; d: nodal meta-
stasis by well-differentiated (G1) squamous cell carcinoma: 
note the nodal rim at lower right corner; e: nodal metastasis 
by moderately differentiated (G2) squamous cell carcinoma; f: 
nodal metastasis by poorly differentiated (G3) squamous cell 
carcinoma: note the nodal tissue at upper right corner.
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An interesting finding was the detection of a 
higher degree of leptin expression in the more su-
perficial and mature layers of laryngeal squamous 
stratified nonkeratinized epithelium in the areas not 
involved by the tumor as well as in the enclosed 
healthy submucosal glands.
Discussion
The positivity to leptin expression in primitive 
tumor tissue we found is in agreement with oth-
er observations reported in the literature regarding 
other neoplastic diseases of head and neck district. 
In particular it was reported in lacrimal glands tu-
mors and salivary glands tumors(16) where different 
hormonal production levels were related to differ-
ences in tumor histological type. 
To date there are many studies about leptin 
expression in breast, bladder, lung, pancreatic, can-
cers and large B cell lymphoma. Specifically high 
leptin levels represent a poor prognostic marker in 
breast, thyroid(17), ovarian, colon and gastric(18) can-
cer, while they may predict a good outcome in soft 
tissue cancer(19). Moreover in their study, for the 
first time, Gallina et al.(15) demonstrated the immu-
nohistochemical expression of leptin in laryngeal 
SCC. In particular they observed its higher expres-
sion in cases of advanced grade tumor (G2-G3) 
and its possible role to predict malignant recur-
rence. In addition, our study revealed leptin pos-
itivity in lymph node SCC metastasis and that its 
immunohistochemical staining positivity level in 
lymph node tissue samples was comparable to the 
primitive laryngeal tumor level only in those cas-
es showing the same histological grade. Though, 
contrary to what observed by Gallina et al.(15), lep-
tin positivity raised with the increase of tumor dif-
ferentiation in both laryngeal primitive tumor and 
lymph node metastasis specimens. 
To the best of our knowledge, no paper has 
been so far published about pathologic tissue sam-
ples coming from lymph node metastasis of epi-
dermoid squamous cell carcinoma. This study can 
therefore be configured as the first in this direction. 
Indeed, up to now, several studies demonstrated 
the correlation between leptin expression and me-
tastasis in different types and sites of tumor such 
as bone metastasis in lung adenocarcinoma (20), 
sentinel lymph node metastasis in cutaneous mela-
noma(21) or even lymph node metastasis in endome-
trial cancer(22). Moreover, these studies didn’t eval-
uate the link between leptin expression levels and 
tumor differentiation as we have done. Therefore 
no one studied the association of leptin expression 
and lymph node metastasis of laryngeal SCC.
The target of our research on leptin expres-
sion in laryngeal squamous neoplastic pathology, 
besides a better prognostic patient stratification, is 
also aimed to the attempt of establishing a more 
precise patient risk stratification possibly identify-
ing a new marker able to give a contribution to the 
identification of patient with poor prognosis and at 
risk of failure of actual standard therapy.
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